Japan granted regulatory approval to the world’s first therapy derived from induced pluripotent stem cells (iPSCs) for Parkinson’s disease, marking a major regulatory milestone for regenerative medicine. The approval opens a pathway for clinical use of iPSC‑based cell therapies and offers a proof point for commercialization of pluripotent‑cell products. The therapy uses patient‑compatible or allogeneic iPSC‑derived dopaminergic neurons to replace cells lost in Parkinson’s disease and is the culmination of decades of preclinical and clinical development in Japan. Regulators cited safety and manufacturing controls as critical components of the approval package. The decision is expected to accelerate investment and development in iPSC platforms globally while prompting scrutiny on long‑term durability, immunogenicity and manufacturing scalability.